Patents by Inventor Jeffrey Roppe
Jeffrey Roppe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230364082Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: ApplicationFiled: July 25, 2023Publication date: November 16, 2023Inventors: Yifeng Xiong, Jeffrey Roppe, Austin Chih-Yu Chen, Yalda Bravo, Thomas Schrader, Jill Melissa Baccei
-
Patent number: 11752149Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: GrantFiled: November 24, 2020Date of Patent: September 12, 2023Assignee: Pipeline Therapeutics, Inc.Inventors: Yifeng Xiong, Jeffrey Roppe, Austin Chih-Yu Chen, Yalda Bravo, Thomas Schrader, Jill Melissa Baccei
-
Publication number: 20230089921Abstract: Provided herein, inter alia, are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: ApplicationFiled: October 6, 2020Publication date: March 23, 2023Inventors: Jill Melissa Baccei, Yalda Bravo, Austin Chih-Yu Chen, Jeffrey Roppe, Thomas Schrader, Yifeng Xiong
-
Publication number: 20210161889Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: ApplicationFiled: November 24, 2020Publication date: June 3, 2021Inventors: Yifeng Xiong, Jeffrey Roppe, Austin Chih-Yu Chen, Yalda Bravo, Thomas Schrader, Jill Melissa Baccei
-
Publication number: 20210155629Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: ApplicationFiled: September 3, 2019Publication date: May 27, 2021Inventors: Thomas Schrader, Yifeng Xiong, Jill Baccei, Jeffrey Roppe, Austin Chen
-
Publication number: 20070219206Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.Type: ApplicationFiled: May 4, 2007Publication date: September 20, 2007Applicant: AMIRA PHARMACEUTICALS, INC.Inventors: John Hutchinson, Petpiboon Prasit, Mark Moran, Jillian Evans, Brian Stearns, Jeffrey Roppe, Bowei Wang, Yen Truong, Yiwei Li, Jasmine Zunic, Jeannie Arruda, Nicholas Stock, Mustapha Haddach, Thomas Seiders, Jill Scott
-
Publication number: 20070105866Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.Type: ApplicationFiled: October 27, 2006Publication date: May 10, 2007Applicant: Amira Pharmaceuticals, Inc.Inventors: John Hutchinson, Petpiboon Prasit, Mark Moran, Jillian Evans, Yiwei Li, Jasmine Zunic, Jeannie Arruda, Nicholas Stock, Brian Stearns, Mustapha Haddach, Jeffrey Roppe
-
Publication number: 20070082067Abstract: Novel triazole compounds represented by Formula (1): (where A, A1, A2, A3, A4, A5, B, R11, W, X, Y and Z are as defined herein) in which the triazole is substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.Type: ApplicationFiled: March 31, 2004Publication date: April 12, 2007Inventors: Nicholas Cosford, Jeffrey Roppe, Lida Tehrani, Bowei Wang
-
Publication number: 20070060618Abstract: The present invention is directed to isotopically labeled alkyne derivative compounds, particularly 11C, 13C, 14C, 18F, 15O, 13N, 35S, 2H, and 3H labeled compounds. In particular, the present invention is directed to 11C, 13C, 14C, 18F, 15O, 13N, 35S, 2H, and 3H labeled heterocyclic alkynes and methods of their preparation. The present invention further includes a method of use of the 11C, 18F, 15O, or 13N labeled heterocyclic alkyne compounds as tracers in positron emission tomography (PET) imaging, particularly in the study of metabolic conditions in mammals, specifically conditions modulated by metabotropic glutamate receptors subtype 5 (mGluR5).Type: ApplicationFiled: October 24, 2003Publication date: March 15, 2007Applicant: MERCK & CO., INC.Inventors: Nicholas David Cosford, Steven Govck, Terence Hamill, Theodore Kamenecka, Thomas Seiders, Jeffrey Roppe, Celine Bonnefous, Donald Burns, Matthew Braun, Dennis Dean, Joseph Simeone
-
Publication number: 20060252807Abstract: The present invention relates to compounds and methods useful as inhibitors of p38 kinase for the treatment or prevention and treatment of diseases such as inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, angiogenic disorders, infectious diseases, neurodegenerative diseases, and viral diseases.Type: ApplicationFiled: April 20, 2006Publication date: November 9, 2006Inventors: Daniel Severance, Elisabeth Gardiner, Stewart Noble, Boliang Lou, Allen Borchardt, Jeffrey Roppe, Mehmet Kahraman, Dana Siegel, Shawn Scranton
-
Publication number: 20060193926Abstract: Pyrrole compounds of Formula (I): and pharmaceutically acceptable salts thereof (where A, B, R11, R12, R13, W, X, Y and Z are as defined herein), which are substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.Type: ApplicationFiled: March 31, 2004Publication date: August 31, 2006Inventors: Nicholas Cosford, Dehua Huang, Jeffrey Roppe, Nicholas Smith, Lida Tehrani
-
Publication number: 20050245542Abstract: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted or unsubstituted six membered heterocyclic ring that includes at least two nitrogen atoms. The ring additionally includes four carbon atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon triple bond. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system. Invention compounds may also act as insecticides, and as fungicides. Pharmaceutical compositions containing invention compounds also have wide utility.Type: ApplicationFiled: April 1, 2005Publication date: November 3, 2005Inventors: Nicholas Cosford, Jeffrey Roppe, Lida Tehrani, Nicholas Smith, Brian Stearns, Dehua Huang, Bowei Wang, Thomas Seiders
-
Publication number: 20050153986Abstract: Tetrazole compounds substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.Type: ApplicationFiled: March 7, 2003Publication date: July 14, 2005Inventors: Chixu Chen, Nicholas Cosford, Brian Eastman, Dehua Huang, Steve Poon, Thomas Reger, Jeffrey Roppe, Nicholas Smith
-
Publication number: 20050085523Abstract: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system.Type: ApplicationFiled: June 23, 2004Publication date: April 21, 2005Inventors: Nicholas Cosford, Theodore Kamenecka, Jeffrey Roppe
-
Publication number: 20050043307Abstract: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system.Type: ApplicationFiled: June 23, 2004Publication date: February 24, 2005Inventors: Nicholas Cosford, Jeffrey Roppe, Lida Tehrani, Nicholas Smith, Brian Stearns, Dehua Huang, Bowei Wang
-
Publication number: 20050020585Abstract: Triazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl which are metabotropic glutamate receptor—subtype 5 (“mGluR5”) modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other diseases.Type: ApplicationFiled: December 13, 2002Publication date: January 27, 2005Inventors: Nicholas Cosford, Petpiboon Prasit, Jeffrey Roppe, Nicholas Smith, Lida Tehrani